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Tardive dyskinesia (TD) is a severe adverse effect induced by prolonged treatment with antipsychotics.
The development of TD is usually associated with advanced age, female sex, prior extrapyramidal adverse
effects, and a longer duration or an intermittent course of antipsychotic treatment. Older age, however, is
the most robust risk factor for TD. Tardive diaphragmatic ﬂutter is an uncommon form of TD and may
lead to great distress in the patient’s life. No effective treatment advice for tardive diaphragmatic ﬂutter
has been suggested. We herein report the case of a 65-year-old male with bipolar disorder who suffered
from tardive diaphragmatic ﬂutter associated with the long-term usage of risperidone. The diaphrag-
matic ﬂutter remitted for 2 years under the monotherapy with aripiprazole. Potential mechanisms, such
as the dopamine stabilization in aripiprazole, are discussed.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Focal uncontrolledwrithing abdominalmovement is not common
and only a few case reports were found in the literature1,2. Dia-
phragmaticﬂutter isonetypeof such involuntarymovement. It canbe
paroxysmal or continuous, and the terms “belly dancer syndrome”
and “Leeuwenhoek’sdisease”werecoinedtodescribe it1,2. Theclinical
manifestations of diaphragmatic ﬂutter are heterogeneous, including
shortness of breath, inspiratory stridor, fatigue, epigastric pulsations,
chest pain and abdominal wall pain3,4. The rhythmic movements
usually disappear during sleep and decrease with respiratory
maneuvers (e.g. deep inspiration). The symptommay be restricted to
the diaphragm5 but frequently involves the accessory respiratory
muscles6, suchas the scalenes and intercostals3. The term “respiratory
myoclonus” is therefore also suggested. The diagnosis of respiratory
myoclonus is based mainly on the clinical presentation, chest ﬂuo-
roscopy, and electromyographic exam3.
2. Case report
A 65-year-oldmale, diagnosedwith bipolar disorder and alcohol
use disorder at 20, was admitted to the psychiatric ward in Juneerest.
sychiatry, Mackay Memorial
w Taipei City 25160, Taiwan.
.
iwan Society of Geriatric Emergen2008 due to progressive abdominal dyskinesia for 5 months. He
had referred rhythmic involuntary movements episodically over
the right upper quadrate abdomen, with tightness and respiratory
difﬁculty. The duration and frequency of dyskinetic episodes
increased gradually and progressed to swallowing dyskinesia,
episodic neck jerks with head nodding, hand tremor, lip pursing,
tongue protruding and squirming. The abnormal involuntary
movement scale (AIMS)7 score was 18 at admission.
During the period from January 2006 to May 2008, his bipolar
symptoms and drinking problems remitted under risperidone
3 mg/day and oxcarbazepine 600 mg/day. In January 2008, he ﬁrst
developed the intermittent abdominal involuntary movement. He
thereafter had a feeling of tight throat, hoarseness, and shortness of
breath. The movement symptoms appeared nearly every day and
each episode lasted for 1 hour. The episode would happen spon-
taneously and mainly while he was in sitting or lying positions. The
movement-related pain also affected his daily life. The evolution of
symptoms during an episode usually began with dyskinesia over
the upper quadrant a few minutes after lying down. The intensity
then increased slowly while in the same position, followed by
abdominal tightness, subjective respiratory difﬁculties, and
hyperventilation. Finally, the elevated anxiety would make the
patient stand up to end the symptoms.
At admission, we gave him biperiden 2.5 mg by intramuscular
injection, but the abdominal dyskinesia got worse 15 minutes later.
Haloperidol 2.5 mg was then injected intramuscularly, and thecy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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including complete blood count, biochemistry, thyroid proﬁle,
vitamin B12, folate levels, and metabolic and immunological panel
were within normal limits. Electromyographic exam over the
abdominal muscles showed regular bursts of muscle contraction of
about 1 Hz, mainly from the diaphragm, which spread to the
abdominal wall. The diaphragm tremorwas impressed. Study of the
nerve conduction velocity demonstrated possible right phrenic
nerve palsy. The results of cerebral and spinal cord magnetic
resonance imaging, electrocardiography, abdominal echography
and abdominal computed tomography scan were unremarkable.
We ﬁrst switched risperidone 3 mg/day to quetiapine 200 mg/
day to attempt to manage the tardive diaphragmatic ﬂutter. The
dyskinesia persisted, however, and quetiapine was switched to
clozapine gradually 11 days later, and oxcarbazepine was dis-
continued. One week later, the overall abdominal dyskinesia had
improved partially in severity and frequency. The AIMS score
decreased from 18 at admission to 5 at discharge in July 2008.
During the follow-up at outpatient clinic, monotherapy with clo-
zapine 100 mg/day continued and adverse effects developed,
including hyper-somnolence, sialorrhea, fatigue, and body weight
gain. The tardive diaphragmatic ﬂutter worsened 4 months after
discharge, and the AIMS score was 7. Due to the intolerable side
effects of clozapine and worse control of tardive diaphragmatic
ﬂutter, aripiprazole was chosen to treat the patient’s bipolar
disorder8,9 and tardive dyskinesia10,11. In December 2008, we
switched clozapine to aripiprazole in a period of 4 weeks and the
dosage of aripiprazole was titrated to 10 mg. The AIMS score
became 3 after using aripiprazole for 4 weeks. No involuntary limb
movement and respiratory difﬁculty were found at this time. In
March 2009, monotherapy with aripiprazole 15 mg/day was
established. In the subsequent 2 years, the patient adhered to the
monotherapy without diaphragmatic ﬂutter and his bipolar
disorder was in remission.
3. Discussion
Typical risk factors associated with the development of tardive
dyskinesia (TD) include older age, pre-existing movement or
neurodegenerative disorders, female sex, the presence of affective
illness, and antipsychotic exposure for longer than 6 months12.
Older age, however, is the most robust risk factor for TD. Over the
age of 65 years, the prevalence of TD is ﬁve to six times greater than
in younger patients13. In this case, the emergence of the abnormal
movement was related to the prolonged use of risperidone and
older age. The antipsychotic-induced tardive symptom may
become permanent and irreversible14, and is less likely to resolve
with increasing age13. Our case also had simultaneous orolinguo-
buccal stereotypes, indicating that the patient’s diaphragmatic
ﬂutter was a variant of TD. It was therefore aggravated by the use of
an anticholinergic drug, biperiden, and ameliorated with the anti-
dopaminergic agent haloperidol.
The pathophysiological mechanisms of TD include: (i) super-
sensitivity of the nigrostriatal dopamine D2 receptors under the
chronic use of antipsychotics; (ii) damage to the striatal g-amino
butyric acid interneurons; and (iii) damage to the striatal cholin-
ergic interneurons15. These mechanisms, however, cannot explain
why only a proportion of patients develop TD during exposure to
the similar antipsychotic. In this case, differential responses to the
therapies with anticholinergic and antidopaminergic agents
implied that the abdominal dyskinesia might be associated with
higher dopaminergic tone. The supersensitive dopaminergic func-
tion would become worse due to the reduced acetylcholine status.Despite there being no consensus in the treatment of TD, the
common approach is to withdraw the offending antipsychotic if
possible16. In the present report, the tardive diaphragmatic ﬂutter
was eventually treated by switching from clozapine to aripiprazole.
It showed that aripiprazole was beneﬁcial and improved dia-
phragmatic ﬂutter and tardive dyskinesia. Aripiprazole, a dihy-
droquinolinone agent, has been reported to treat cases with TD and
improved the involuntary symptoms through its unique mecha-
nism of action10,11,17,18. The effect might arise from the partial
agonism of 5-hydroxytryptamine 1A and D2 receptors, and antag-
onism of 5-hydroxytryptamine 2A receptors. Some have sug-
gested10,11 that D2 partial antagonism may normalize D2-receptor
function in patients with TD. Aripiprazole causes “functionally
selective” activation of D2 (and possibly D3)-dopamine receptors19,
and thus acts like a dopamine system stabilizer. Aripiprazole
exhibits activity as a dopamine agonist in relation to the hypo-
dopaminergic condition, while acting like a dopamine antagonist
when at the hyperdopaminergic status. The evidence shows that
the use of aripiprazole causes little D2 receptor up-regulation20,
Therefore it may be used to prevent or treat the TD.
In summary, our report provides a possible way to manage
diaphragmatic ﬂutter and TD.We demonstrated a successful switch
from clozapine to aripiprazole to treat an elderly patient’s mental
disorders and involuntary movements.
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